VERZENIO™ (abemaciclib) is approved for HR+/HER2- advanced or metastatic breast cancer. VERZENIO is a prescription medicine used:
- in combination with fulvestrant to treat women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer whose disease has progressed after hormonal therapy.
- alone to treat adults with HR- positive, HER2- negative advanced breast cancer or metastatic breast cancer whose disease has progressed after hormonal therapy and prior chemotherapy.
Due to our oncology focus, and extensive experience handling oral oncology medications, Onco360 has been selected as one of the handful of pharmacies across the country that can dispense VERZENIO.
Put the Oncology Pharmacy experts at Onco360 to work for your breast cancer patients today.
1VERZENIO Prescribing Information: 2017, Eli Lilly and Company. VERZENIO™ trademark is owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.